23andMe Reports Third Quarter Fiscal Year 2025 Financial Results

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges

SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe,” the “Company,” “we,” “us,” and “our”), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, reported its financial results for the third quarter (“Q3”) of fiscal year 2025 (“FY25”), which ended December 31, 2024.